The Justa & Lars Honors Bob Brinker Investment Club Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Pastimes : The Justa & Lars Honors Bob Brinker Investment Club

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Mike McFarland who wrote (10262)	12/5/1999 12:39:00 PM
From: marc ultra	Read Replies (1) of 15132

OT Mike, Just to let you know a main reason Celgene has taken off is because of thalidomide off label sales which should continue to increase now that the impressive multiple myeloma results were reported in the New England Journal of Medicine. ENMD had the rights to all cancer uses of thalidomide but instead partnered with CELG and gets a percent of any sales of thalidomide that CELG makes for any purpose. Also I would say that the pre-clinical results on endostatin and angiostatin leave a strong possibility that the endostatin human trials now underway at three centers might blow away what has been seen so far in any angiogenesis inhibitor. It could also be a bust of course but this is a discussion for a different forum Marc

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next